Exact Sciences announced today the results from its ALTUS Study, which is the largest prospective trial of a blood test for liver cancer surveillance in the United States, with more than 3,000 participants.

According to a release, the Oncoguard Liver test detected three times more cancers compared to the current standard of care. The test also demonstrated a specificity of 82% in the ALTUS study, which exceeded the threshold established by experts for clinical utility.

“These new data from the ALTUS study show that we can reliably detect liver cancer earlier, which is key to improving outcomes,” Exact Sciences Chief Medical Officer Dr. Paul Limburg said in a statement. “With Cologuard, we have already seen what is possible, with more than 20 million tests completed and thousands of colorectal cancers prevented through early detection. The Oncoguard Liver test builds on that success, applying the same science-driven approach to another cancer in which finding disease early can help save lives.”

As previously reported, the Oncoguard Liver test is a blood-based multiomics assay developed in collaboration with Mayo Clinic.